Cargando…
Direct oral anticoagulant use and risk of severe COVID‐19
BACKGROUND: Hypercoagulability and thromboembolism are prominent features of severe COVID‐19, and ongoing anticoagulant use might be protective. METHODS: We conducted a nationwide register‐based cohort study in Sweden, February through May, 2020, to assess whether ongoing direct oral anticoagulant (...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753564/ https://www.ncbi.nlm.nih.gov/pubmed/33258156 http://dx.doi.org/10.1111/joim.13205 |